Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
September - SAG meeting
Volgen
Kiadis Pharma announces results for the six months ended June 30, 2019 Kiadis to hold conference call with investors today at 15:00 CEST Amsterdam, The Netherlands, September 10, 2019 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces its unaudited interim results for the six months ended June 30, 2019, which have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union. Arthur Lahr, CEO of Kiadis Pharma, commented: “In the first six months of 2019, through the acquisition of Cytosen, we have transformed Kiadis into a company with two cell therapy platforms to help patients with life-threatening diseases. Kiadis now has a pipeline with therapies in all stages of development focused on both hematopoietic stem cell transplantation (HSCT) and novel cell therapies for patients with cancer. Through these programs we are leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.” Mr. Lahr continued: “While the review by the European Medicines Agency of the marketing authorization application continues, we have advanced the global phase 3 study for ATIR101 with major transplant centers in the US, EU, Canada and Israel participating in the study; and we plan to open the NK-REALM transplant phase 1/2 study for CSTD002 and a NK phase 1/2 study to treat AML R/R patients in 2020.” Operating highlights (including post-reporting period) • Kiadis’ marketing authorization application (MAA) for ATIR101 is currently under review. Kiadis responded to the day 180 outstanding issues in May 2019. In early September, the Committee for Advanced Therapeutics (CAT) convened a Strategic Advisory Group (SAG) related to the review of the application; the next step in the regulatory process is for the application to be reviewed by the CAT in October. The company continues to expect to receive a decision from the EMA in 2020. • The global phase 3 trial for ATIR101, CR-AIR-009, is ongoing. The study, which will enroll approximately 250 patients, is comparing ATIR101 to the post-transplant cyclophosphamide (PTCy) or ‘Baltimore’ protocol. • In June, after receiving customary shareholder approvals, Kiadis closed the transaction to acquire US-based CytoSen Therapeutics, Inc. The combination of Kiadis and CytoSen creates a leader in cell-based cancer immunotherapy, with complementary T-Cell and NK-cell platforms. • In the first half of 2019, Kiadis raised gross proceeds of €27.6 million through a private placement of 3,684,200 shares. As of June 30, 2019 Kiadis had €62.7 million in cash and cash equivalents. Financial highlights for the six months ended June 30, 2019 (including post reporting period) (Amounts in EUR million, except per share data) 2019 2018 Change Total revenue and other income - - - Total operating expenses (25.7) (11.1) (14.6) Research and development (16.2) (7.7) (8.5) General and administrative (9.5) (3.4) (6.1) Operating result (25.7) (11.1) (14.6) Net financial result (0.2) (3.0) 2.8 Net result (25.9) (14.1) (11.8) Net operating cash flow (21.4) (10.6) (10.8) Cash position at end of period 62.7 60.3 2.4 Equity 59.7 44.1 15.6 Earnings per share before dilution (EUR) (1.03) (0.74) (0.29) Financial highlights for the six months ended June 30, 2019, presented above and discussed below, include less than one month of activity related to the operations of CytoSen Therapeutics Inc. from the completion of the acquisition in early June 2019. The comparable period of 2018 does not include any results of CytoSen Therapeutics operations. Operating expenses • Operating expenses increased to EUR 25.7 million in 2019 from EUR 11.1 million in 2018, an increase of EUR 14.6 million. • Research and Development expenses increased to EUR 16.2 million in 2019 from EUR 7.7 million in 2018. Without the expenses for share-based compensation, Research and Development expenses increased to EUR 15.3 million in 2019 from EUR 7.3 million in 2018, an increase of EUR 8.0 million. This increase was primarily caused by a further expansion of the workforce in all areas of the organization, clinical expenses related to the CR-AIR-009 study, the move to a larger building which includes a commercial manufacturing facility, laboratories and office space. • General and Administrative expenses increased to EUR 9.5 million in 2019 from EUR 3.4 million in 2018. Without the expenses for share-based compensation, General and Administrative expenses were EUR 5.4 million higher at EUR 8.4 million in 2019 compared to EUR 3.0 million in 2018. The increase was due to the expansion of the workforce, higher consultancy expenses related to market access preparations, financing rounds and the acquisition of CytoSen. Operating results • As a result of the overall increase in total operating expenses, the Group's operating loss increased EUR 14.6 million from EUR 11.1 million in 2018 to EUR 25.7 million in 2019. Net financial result • Net finance expenses for 2019 decreased to EUR 0.2 million from EUR 3.0 million in 2018. The decrease of EUR 2.8 million is due to favorable results of the adjustments of loans of EUR 1.2 million, favorable results of net foreign exchange of EUR 1.1 million and favorable fair value adjustments of EUR 0.7 million related to the contingent consideration of CytoSen in 2019 and unfavorable fair value adjustment of derivatives in 2018. Net result • As a result of the above items, the loss for the year to date increased by EUR 11.8 million to EUR 25.9 million in 2019 versus a loss of EUR 14.1 million in 2018. Cash position • The Company strengthened cash position in 2019 with private placements of 3.7 million ordinary shares raising net proceeds of EUR 25.4 million • The cash position increased by EUR 2.4 million to EUR 62.7 million at June 30, 2019 compared to EUR 60.3 million at the end of 2018. This increase mainly results from the net proceeds of the share offering for a total amount of EUR 25.4 million and EUR 3.1 million cash balances as part of the assets of CytoSen. In 2019, the net operating cash outflow amounted to EUR 21.4 million and further included the acquisition of PP&E, repayments of loans and lease liabilities for a total amount of EUR 4.8 million. • The Company’s cash position at June 30, 2019 was EUR 62.7 million. Equity • The Company's equity position amounted to EUR 59.7 million at June 30, 2019 versus EUR 44.1 million at the end of 2018, an increase of EUR 15.6 million. The main drivers of this increase are net proceeds of the share offerings of EUR 25.4 million, shares issued upon the acquisition of CytoSen for EUR 14.5 million, partly offset by the loss for the year of EUR 25.9 million and currency translation of EUR 0.4 million. Earnings per share • The undiluted loss per share for 2019 increased to EUR 1.03 compared to EUR 0.74 in 2018. A full financial report for the six months ended June 30, 2019 is available on Kiadis Pharma’s website at www.kiadis.com/financial-news/.
De cash positie valt mij erg mee. Had lager verwacht.
BassieNL schreef op 10 september 2019 07:11 :
Review bij CAT in oktober.
Dus precies zoals @kompas steeds meldde.
Ja, dat is volgens mij ook goed nieuws Bassie! Vanuit Kiadis begreep ik dat dit de snelst mogelijke route zou zijn in geval van een mogelijk direct positief SAG advies. Dit kan/mag men vanuit Kiadis nu natuurlijk niet hardop uitspreken.
We kunnen in ieder geval met deze cashpositie nog een jaar vooruit. Verder valt of staat alles met de goedkeuring.
Mozes kriebel schreef op 10 september 2019 07:17 :
De cash positie valt mij erg mee. Had lager verwacht.
Mij niet. Ik kan de kaspositie niet plaatsen. 42 mio eind mei (volgens emissie document) +25,4 mio aan netto emissie opbrengsten + 5,2 mio cash Cytosen (6 mio USD, verder een cashless deal) = 72,6 mio cash exclusief de cashburn van juni. En dan is er eind juni nog maar 62,7 mio over. Dus er is 10 mio doorheen gedraaid in de maand juni? Dat kan toch niet? Waar zit mijn fout? Als de cash van Cytosen niet is meegeteld klopt klopt het sommetje wel aardig.
mr.Franz schreef op 10 september 2019 07:20 :
We kunnen in ieder geval met deze cashpositie nog een jaar vooruit. Verder valt of staat alles met de goedkeuring.
De Kaspositie is inderdaad ook prima te noemen! Al met al ben ik zeer tevreden met de berichtgeving van vandaag.
Had liever gehad dat de goedkeuring er geweest was
mr.Franz schreef op 10 september 2019 07:20 :
We kunnen in ieder geval met deze cashpositie nog een jaar vooruit. Verder valt of staat alles met de goedkeuring.
Bij de laatste 2 emissies was er nog ca. 42 miljoen in kas, als ze die trend doorzetten, zit je met de huidige cashburn al in november/december tegen een nieuwe emissie aan te kijken...
een plus of min. wat verwachten we.
Dennis plat schreef op 10 september 2019 07:44 :
Had liever gehad dat de goedkeuring er geweest was
Dat is koersgevoelige informatie en mag niet mee gewacht worden tot de cijfers
Dennis plat, dat noemen wij een open deur intrappen!
Vooralsnog een lagere opening verwacht.
Conclusie? Of er wel of geen goedkeuring is vanuit de SAG is nog niet bekend --> in Oktober weten we dit pas?
Kompas schreef op 10 september 2019 07:28 :
[...]
De Kaspositie is inderdaad ook prima te noemen!
Al met al ben ik zeer tevreden met de berichtgeving van vandaag.
had je dan minder cash verwacht?
Kouwe 81 schreef op 10 september 2019 08:14 :
Conclusie?
Of er wel of geen goedkeuring is vanuit de SAG is nog niet bekend --> in Oktober weten we dit pas?
Tussen de lijnen door lees ik dat het SAG-team geen belemmeringen ziet, Kiadis krijgt namelijk gelijk terugkoppeling conform informatie Bassie. Nu moet de CAT kijken naar het oordeel van de SAG, daarna CHMP, dus ik denk dat we kunnen concluderen dat we de heuvel SAG goed hebben beklommen! CC van vanmiddag afwachten, zal wel de nodige vragen hiernaar gesteld worden.
Theoretical Opening Price 6.00
BassieNL schreef op 10 september 2019 08:15 :
[...]had je dan minder cash verwacht?
Nee, was meer een bevestiging deze voor dit moment prima te vinden. Met de mogelijkheid van een direct positief SAG advies nog openstaand en op de CAT agenda voor Oktober ben ik absoluut tevreden met het halfjaarbericht van vandaag. Theoretische openings koersen zijn uberhaupt nietszeggend en "de daghandel" kan altijd eerst nog wat aan de boom proberen te schudden maar ik zie het aandeel nu wel verder gaan oplopen richting Oktober.
Kouwe 81 schreef op 10 september 2019 08:14 :
Conclusie?
Of er wel of geen goedkeuring is vanuit de SAG is nog niet bekend --> in Oktober weten we dit pas?
Goedkeuring zou niet komen vanuit de SAG. Die is geraadpleegd. Goedkeuring wordt in 2020 verwacht. Signalen wijzen m.i. de goede kant uit. The company continues to expect to receive a decision from the EMA in 2020, p.3.
Wel jammer dat dit allemaal zo lang moet duren. Als dit middel werkt, heeft de hele doorlooptijd voor goedkeuring zo lang geduurd... :s Maargoed, ik snap ook dat men goed onderzoek moet doen naar de werking alvorens dit op de markt gezet mag worden. Maar dan nog :)
ArnoNieme schreef op 10 september 2019 08:31 :
[...]
Goedkeuring zou niet komen vanuit de SAG. Die is geraadpleegd. Goedkeuring wordt in 2020 verwacht. Signalen wijzen m.i. de goede kant uit.
The company continues to expect to receive a decision from the EMA in 2020, p.3.
Klopt, maar een conclusie van SAG krijg je wel te horen. E.e.a. is door Bassie destijds in een officieel document gedeeld, echter ben ik niet van plan 38 pagina's terug ernaar te zoeken :-)
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
860,01
-0,62%
EUR/USD
1,0655
+0,11%
FTSE 100
7.895,85
+0,24%
Germany40^
17.714,20
-0,69%
Gold spot
2.392,50
0,00%
NY-Nasdaq Composite
15.282,01
-2,05%
Stijgers
Dalers